These growth shares are my best buys for November

Appen Ltd (ASX:APX) shares and two others are my best growth picks for November after their declines last month…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I think it is fair to say that October was a month to forget for Australian investors.

I'm optimistic that November will be significantly better and that a number of beaten down growth shares will recover some off their sizeable declines.

Three that I would consider buying are as follows:

Appen Ltd (ASX: APX)

This global leader in the development of high-quality, human annotated datasets for machine learning and artificial intelligence could be a great option in November. It was one of the worst performers on the Australia share market in October due to the tech selloff. While this was disappointing for shareholders, I believe it is a buying opportunity for non-shareholders. At present Appen's shares are changing hands at 27x estimated FY 2019 earnings. I think this is great value given its strong long-term growth potential.

Aristocrat Leisure Limited (ASX: ALL)

Another tech share that fell heavily last month was Aristocrat Leisure. But unlike many of its tech peers, I felt that its shares were already trading at an attractive price prior to the selloff. In light of this, I think they are arguably in the bargain bin now at just 20x estimated FY 2019 earnings. Especially given the solid growth potential of its fledgling digital business. Management believes this business is well positioned to address a broad spectrum of opportunities in the US$50 billion mobile gaming market.

Bellamy's Australia Ltd (ASX: BAL)

The Bellamy's share price is another growth share that fell heavily in October. However, this was largely down to disappointing guidance given for FY 2019. Management expects Australian label sales to be flat in FY 2019 due to the disruption caused by the launch of a new production formulation. While this is very underwhelming, I think investors should look beyond FY 2019 and to the future. At its annual general meeting management confirmed that it is targeting sales of $500 million by the end of FY 2021. This will be a 52% increase on FY 2018's result.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Appen Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

2 ASX growth shares to snap up while they're still down

Brokers see plenty of upside for these mainstay sector picks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

Why these ASX growth stocks could be much bigger in 2030 than today

These stocks have long growth runways and strong business models.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Growth Shares

3 incredible ASX growth shares to buy and hold forever in 2026

True long-term investing means owning businesses you’d be happy to hold through volatility, uncertainty, and decades of change.

Read more »

Happy work colleagues give each other a fist pump.
Growth Shares

2 shares to buy hand over fist before the ASX 200 soars higher in 2026

These shares are highly rated by brokers for a reason. Here's what you need to know about them.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Experts rate these 2 ASX shares as buys this month!

Leading analysts say these stocks are a buy.

Read more »

Happy healthcare workers in a labs
Technology Shares

Prediction: CSL shares could soar past $270 in 2026

Here's what to expect from the Australian-based global biotechnology company this year.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 unstoppable ASX 200 stocks to buy in 2026 and hold forever

These blue chips could have very bright futures. Do you own them?

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

5 incredible ASX growth stocks to buy for 2026

These growth stocks could be well-positioned for the long-term.

Read more »